Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19.

Autor: Almasi S; Department of Rheumatology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran., Rashidi A; Immunoregulation Research Center, Shahed University, Tehran, Iran., Kachuee MA; Department of Radiology, Firouzgar Hospital, Iran University of Medical Science, Tehran, Iran., Shirazi BM; Immunoregulation Research Center, Shahed University, Tehran, Iran., Izadi S; Department of Pulmonology, Firuzgar Hospital, Iran University of Medical Science, Tehran, Iran., Ghaffarpour S; Immunoregulation Research Center, Shahed University, Tehran, Iran., Azimi M; Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Science, Tehran, Iran., Naghizadeh MM; Non-communicable Diseases Research Center, Fasa University of Medical Science, Fasa, Iran., Makiani MJ; Department of Infectious Disease, Antimicrobial Resistance Research Center, Institute of Immunology & Infectious Disease, School of Medicine Sciences, Tehran, Iran., Ranjbar M; Department of Infectious Diseases, Iran University of Medical Science, Tehran, Iran., Goudarzi M; Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Science, Tehran, Iran., Rahimian N; Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Science, Tehran, Iran., Ghazanfari T; Immunoregulation Research Center, Shahed University, Tehran, Iran; Department of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran. Electronic address: tghazanfari@yahoo.com.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2023 Sep; Vol. 122, pp. 110565. Date of Electronic Publication: 2023 Jun 30.